RNA-seq and ChIP-seq in HepG2 hepatocellular carcinoma and U87 glioblastoma cells with CRISPRi knockdown of ACTR5

This dataset examined the effect of ACTR5 knockdown in HepG2 and U87 cells. The gene expression profiling (RNA-seq) and the chromatin targeting of ACTR5 (TST-ChIP-seq) are reported. Overall design: RNAseq:dCas9-Krab-expressing HepG2 and U87 cells were transduced with sgiNTC and sgiACTR5. The total RNA was extracted using the RNeasy Mini Kit (74104, QIAGEN) and submitted for RNA-seq at Novogene (PE150, NovoSeq6000). TST-ChIP-seq: ACTR5-TST cautured genomic DNA was submitted for ChIP-seq at Novogene (PE150, NovaSeq6000).

本数据集探究了ACTR5基因敲低在HepG2与U87细胞中的效应。本研究报道了基因表达谱（RNA测序（RNA-seq））以及ACTR5的染色质靶向特征（TST染色质免疫沉淀测序（TST-ChIP-seq））。总体实验设计如下：RNA测序组：将表达dCas9-Krab的HepG2及U87细胞分别转导sgiNTC与sgiACTR5。采用RNeasy Mini试剂盒（货号74104，QIAGEN）提取总RNA，随后送至诺禾致源（Novogene）开展RNA-seq测序，测序模式为PE150，使用NovaSeq6000测序平台。TST-ChIP测序组：将ACTR5-TST捕获的基因组DNA送至诺禾致源开展ChIP-seq测序，测序模式为PE150，使用NovaSeq6000测序平台。